Company news

HLS Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

HLS Therapeutics to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

April 23, 2019

HLS Therapeutics Granted Priority Review Status from Health Canada for Vascepa®

March 29, 2019

HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results

March 21, 2019

HLS Therapeutics Inc. Opens the Market

March 20, 2019

HLS Therapeutics Announces Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT(TM)

March 19, 2019

HLS Therapeutics Announces High Risk of Atherosclerotic Cardiovascular Events Projected in People with Elevated Triglycerides Without Established Atherosclerotic Cardiovascular Disease

March 19, 2019

HLS Therapeutics Licenses and Files 'Athelas One' Point-of-Care Device

March 14, 2019

HLS Therapeutics to Host 2018 Fourth Quarter and Year-End Financial Results Conference Call

March 7, 2019

HLS Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference

February 19, 2019

HLS Therapeutics Announces Graduation to the Toronto Stock Exchange

February 6, 2019

HLS Therapeutics Receives Conditional Approval to Graduate to the Toronto Stock Exchange

January 29, 2019

HLS Therapeutics Announces Q3 2018 Financial Results

November 15, 2018

HLS Therapeutics Announces that Amarin's Vascepa ® (icosapent ethyl) Demonstrates 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attack and Stroke in REDUCE-IT(TM), which Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event Primary Composite Endpoint

November 12, 2018

HLS Therapeutics to Host 2018 Third Quarter Results Conference Call

November 1, 2018

HLS Therapeutics Announces that Amarin's REDUCE-IT(TM) Cardiovascular Outcomes Study of Vascepa® (icosapent ethyl) Capsules Met Primary Endpoint

September 24, 2018

HLS Therapeutics Appoints Tim Hendrickson as CFO

September 6, 2018

HLS Therapeutics Announces Grant of Stock Options

August 22, 2018

HLS Therapeutics Announces Q2 2018 Financial Results

August 15, 2018

HLS Therapeutics to Host 2018 Second Quarter Results Conference Call

July 30, 2018

HLS Therapeutics to Host Annual Shareholder Meeting

June 15, 2018

HLS Therapeutics Enters into Automatic Share Purchase Plan

May 30, 2018

HLS Therapeutics Announces Q1 2018 Financial Results

May 16, 2018

HLS Therapeutics Announces Normal Course Issuer Bid

May 9, 2018

HLS Therapeutics to Host 2018 First Quarter Results Conference Call

May 9, 2018

HLS Appoints Ryan Lennox as General Counsel

May 7, 2018

HLS Therapeutics Announces Partial Redemption of Preferred Shares

April 26, 2018

HLS to Present at the 2018 Bloom Burton & Co. Healthcare Investor Conference

April 20, 2018

HLS Therapeutics Announces Fiscal 2017 Financial Results

March 29, 2018

HLS Therapeutics to Host 2017 Fourth Quarter and Year End Results Conference Call

March 19, 2018

← Newer news releases

Calls

The 5 newest of 7 calls. Every call is listed under its year.

Decks

The 5 newest of 28 decks. Every deck is listed under its year.